Floatz logo

17 allylamino-17-demethoxygeldanamycin

Recurrent Adult Hodgkin Lymphoma

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

150 Active assets in the Recurrent Adult Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB

View all 50 →

Same molecule, other indications

17 allylamino-17-demethoxygeldanamycin is also rated in:

Adult Lymphocyte Depletion Hodgkin LymphomaDormant
B
Indicative ·
57 / 100
View asset →
von Hippel-Lindau diseaseDormant
B
Indicative ·
57 / 100
View asset →
Hodgkin's lymphoma, mixed cellularityDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →